Edition:
India

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

2.37USD
12:24am IST
Change (% chg)

$-0.09 (-3.66%)
Prev Close
$2.46
Open
$2.45
Day's High
$2.46
Day's Low
$2.30
Volume
457,299
Avg. Vol
869,026
52-wk High
$12.30
52-wk Low
$2.27

Latest Key Developments (Source: Significant Developments)

Immunogen Announces Sale Of Residual Kadcyla Royalties
Wednesday, 9 Jan 2019 

ImmunoGen Inc ::IMMUNOGEN ANNOUNCES SALE OF RESIDUAL KADCYLA ROYALTIES.IMMUNOGEN INC - COMPANY TO RECEIVE $65 MILLION PAYMENT.IMMUNOGEN INC - OMERS NOW OWNS 100% OF IMMUNOGEN'S RIGHTS TO RECEIVE KADCYLA ROYALTIES.IMMUNOGEN INC - TRANSACTION ENTAILS SALE OF RESIDUAL INTEREST HELD BY CO FROM A PRIOR TRANSACTION WITH IMMUNITY ROYALTY HOLDINGS, L.P..  Full Article

ImmunoGen Announces Resignation Of Chief Financial Officer
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - ImmunoGen Inc ::IMMUNOGEN ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER.SAYS CFO DAVID B. JOHNSTON RESIGNED.JOHNSTON WILL REMAIN EMPLOYED WITH COMPANY THROUGH END OF 2018.MARK ENYEDY, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL SERVE ON AN INTERIM BASIS AS COMPANY'S PRINCIPAL FINANCIAL OFFICER.DAVID FOSTER, VICE PRESIDENT OF FINANCE AND CHIEF ACCOUNTING OFFICER, WILL CONTINUE TO OVERSEE CO'S FINANCE AND ACCOUNTING FUNCTIONS.SEARCH HAS BEEN INITIATED TO IDENTIFY A NEW CHIEF FINANCIAL OFFICER.  Full Article

ImmunoGen Q3 Loss Per Share $0.32
Friday, 2 Nov 2018 

Nov 2 (Reuters) - ImmunoGen Inc ::IMMUNOGEN REPORTS RECENT PROGRESS AND THIRD QUARTER 2018 OPERATING RESULTS.Q3 LOSS PER SHARE $0.32.Q3 REVENUE $10.9 MILLION VERSUS I/B/E/S VIEW $13.1 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.IMMUNOGEN - QTRLY OPERATING EXPENSES INCLUDED $0.9 MILLION RESTRUCTURING CHARGE DUE TO PREVIOUSLY ANNOUNCED WORKFORCE REDUCTION.SEES 2018 CASH AND CASH EQUIVALENTS BETWEEN $250 MILLION AND $255 MILLION.SEES 2018 REVENUES BETWEEN $50 MILLION AND $55 MILLION.SEES 2018 OPERATING EXPENSES BETWEEN $215 AND $220 MILLION.IMMUNOGEN-SEES CURRENT CASH, EXPECTED CASH REVENUE FROM PARTNERS, COLLABORATORS TO FUND OPERATIONS AT LEAST A YEAR BEYOND FORWARD I PHASE 3 TRIAL TOP-LINE RESULTS.  Full Article

Immunogen Announces FDA Fast Track Designation For Mirvetuximab Soravtansine
Monday, 18 Jun 2018 

June 18 (Reuters) - ImmunoGen Inc ::IMMUNOGEN ANNOUNCES FDA FAST TRACK DESIGNATION FOR MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.IMMUNOGEN - ENROLLMENT OF FORWARD I WAS COMPLETED AHEAD OF SCHEDULE IN APRIL 2018, EXPECTS TO REPORT TOP-LINE RESULTS FROM FORWARD I TRIAL IN H1 2019.  Full Article

Immunogen Inc Files For Potential Mixed Shelf Offering‍​
Thursday, 8 Mar 2018 

March 7 (Reuters) - Immunogen Inc ::IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING‍​.  Full Article

Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11‍​
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Immunogen Inc ::IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS.QTRLY NET LOSS PER COMMON SHARE, BASIC AND DILUTED $0.11‍​.SEES FY 2018 REVENUE $60 MILLION TO $65 MILLION.QTRLY TOTAL REVENUES $39.45 MILLION VERSUS $13.85 MILLION.IMMUNOGEN - EXPECTS CURRENT CASH COMBINED WITH EXPECTED CASH REVS FROM PARTNERS & COLLABORATORS WILL ENABLE CO TO FUND ITS OPERATIONS INTO Q4 OF 2019.Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $32.7 MILLION -- THOMSON REUTERS I/B/E/S.SEES CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2018 BETWEEN $115 MILLION AND $120 MILLION.FY2018 REVENUE VIEW $58.7 MILLION -- THOMSON REUTERS I/B/E/S.IMMUNOGEN SAYS TO MOVE TO OPERATING MODEL THAT WILL RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG SUBSTANCE.IMMUNOGEN - TO MOVE TO OPERATING MODEL THAT WILL ALSO RELY ON EXTERNAL MANUFACTURING AND QUALITY TESTING FOR DRUG PRODUCT FOR DEVELOPMENT PROGRAMS.DECOMMISSIONING NORWOOD FACILITY WILL RESULT IN ANTICIPATED COST SAVINGS OF OVER $20 MILLION DURING NEXT FIVE YEARS.IMMUNOGEN -IMPLEMENTING ‍NEW OPERATING MODEL TO LEAD TO RAMP-DOWN OF MANUFACTURING, QUALITY ACTIVITIES AT NORWOOD, MASSACHUSETTS FACILITY BY 2018 END​.‍ IMPLEMENTATION OF NEW OPERATING MODEL WILL LEAD TO FULL EXIT AT NORWOOD, MASSACHUSETTS FACILITY BY EARLY 2019​.Q4 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.  Full Article

Immunogen Authorized Ramp-Down Of Activities At Norwood, MA
Friday, 9 Feb 2018 

Feb 8 (Reuters) - Immunogen Inc ::IMMUNOGEN - BOARD AUTHORIZED NEW OPERATING MODEL WHICH WILL LEAD TO RAMP-DOWN OF ACTIVITIES AT NORWOOD, MASSACHUSETTS FACILITY BY END OF 2018.IMMUNOGEN SAYS FULL DECOMMISSIONING OF NORWOOD, MASSACHUSETTS FACILITY EXPECTED BY EARLY 2019 - SEC FILING.IMMUNOGEN INC - IMPLEMENTATION OF NEW OPERATING MODEL WILL RESULT IN A NET REDUCTION OF WORKFORCE BY ABOUT 20 POSITIONS BY END OF 2018.IMMUNOGEN INC IMPLEMENTATION OF NEW OPERATING MODEL EXPECTED TO CAUSE ONE-TIME CHARGE OF UP TO $2.5 MILLION FOR SEVERANCE Q1 OF 2018.IMMUNOGEN INC - DECOMMISSIONING NORWOOD FACILITY WILL RESULT IN ANTICIPATED COST SAVINGS OF OVER $20 MILLION DURING NEXT FIVE YEARS.  Full Article

Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Immunogen Inc ::IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING.  Full Article

ImmunoGen reports Q3 loss per share $0.61
Friday, 3 Nov 2017 

Nov 3 (Reuters) - ImmunoGen Inc :ImmunoGen reports recent progress and third quarter 2017 operating results.Q3 loss per share $0.61.Q3 revenue $8.5 million versus $7.7 million.Q3 revenue view $33.6 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.ImmunoGen Inc - ‍Has updated its guidance for 2017​.Revenue guidance remains unchanged and is expected to be between $115 million and $120 million.ImmunoGen Inc - ‍Cash and cash equivalents at December 31, 2017 are expected to be between $260 million and $265 million​.ImmunoGen- Operating expenses for 2017 are now expected to be between $170 and $175 million, compared to previous guidance of $175 to $180 million.ImmunoGen - Expects current cash combined with expected cash revenue from partners & collaborators will enable co to fund operations into Q4 2019​.  Full Article

ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock
Friday, 1 Sep 2017 

Sept 1 (Reuters) - ImmunoGen Inc :ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock.ImmunoGen Inc - ‍Company anticipates that exchanges will be completed on or about September 11, 2017​.ImmunoGen Inc - Aggregate principal amount of company's 4.50% convertible senior notes due 2021 is anticipated to be reduced to approximately $23.6 million​.ImmunoGen Inc - Co ‍will exchange about 16.5 million newly issued shares of company's common stock​.  Full Article

ImmunoGen drug fails cancer study, shares slide 40 percent

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.